Despite these two rather unfavorable aspects regarding the practicability of CXCR4-RLT in solid tumors, one has to consider that a substantial portion of patients were diagnosed with difficult-to-treat tumor entities, including ACC. This evidence concerns the gene CXCR4 and neoplasm.